Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia |
| |
| Authors: | Sule Unal MD Fehime Kara MD Seza Ozen MD Diclehan Orhan MD Murat Tuncer MD Fatma Gumruk MD |
| |
| Affiliation: | 1. Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Hacettepe University, Ankara, Turkey;2. Faculty of Medicine, Department of Pediatrics, Hacettepe University, Ankara, Turkey;3. Faculty of Medicine, Department of Pediatrics, Division of Pediatric Nephrology & Rheumatology, Hacettepe University, Ankara, Turkey;4. Professor.;5. Faculty of Medicine, Department of Pediatrics, Division of Pediatric Pathology, Hacettepe University, Ankara, Turkey |
| |
| Abstract: | Severe essential cryofibrinogenemia is rare in childhood, and both the diagnosis and the management are challenging for pediatricians. An 11‐year‐old male, who had already lost two digits following cold exposure, was referred after multiple visits to various hospitals and subsequently diagnosed as primary cryofibrinogenemia. His history revealed unresponsiveness to calcium channel blockers, acetyl salicylic acid, pentoxifylline, dextran, and steroids. Stanozolol (2 mg/day, orally) prophylaxis was initiated and no new skin lesions developed following starting this treatment. Some of the newly formed lesions at the onset of stanozolol healed. Pediatr Blood Cancer 2010;55:174–176. © 2010 Wiley‐Liss, Inc. |
| |
| Keywords: | cryofibrinogenemia pediatric stanozolol |
|
|
